Thermo Fisher Scientific Aktie
| 571,84USD | 4,50USD | 0,79% |
WKN: 857209 / ISIN: US8835561023
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 80 000 | 130 000 | 130 000 | 122 000 | 125 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,40 | 0,30 | 0,35 | 0,35 | 0,34 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 21 957 | 20 113 | 25 229 | 24 589 | 22 137 |
| Summe Anlagevermögen | 47 095 | 75 010 | 71 925 | 74 137 | 75 184 |
| Summe Aktiva | 69 052 | 95 123 | 97 154 | 98 726 | 97 321 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 34 545 | 54 146 | 53 006 | 51 884 | 47 650 |
| Summe Eigenkapital | 34 507 | 40 977 | 44 148 | 46 842 | 49 671 |
| Summe Passiva | 69 052 | 95 123 | 97 154 | 98 726 | 97 321 |
Adresse
| 168 Third Avenue, 02451 Waltham | |
| Telefon | +1 (781) 622-1000 |
| Internet | http://www.thermofisher.com |
Management
|
Aditya Joshi
Chief Strategy Officer & Vice President |
|
Anthony Hugh Smith
Treasurer, Vice President-Tax & Treasury |
|
C. Martin Harris
Independent Director |
|
Daniel P. Shine
Senior VP, President-Analytical Instruments |
|
Daniella Cramp
Senior VP & President-BioProduction Group |
|
Debora L. Spar
Independent Director |
|
Dion J. Weisler
Non-Executive Director |
|
Frederick M. Lowery
President-Laboratory Products & Bioproduction |
|
Gianluca Pettiti
Executive Vice President |
|
James C. Mullen
Independent Director |
|
Jennifer M. Johnson
Independent Director |
|
John Brian Sabo
VP & General Counsel-Customer Channels Group |
|
Joseph R. Holmes
Chief Accounting Officer & Vice President |
|
Julia L. Chen
Secretary & Vice President |
|
Karen E. Nelson
Chief Scientific Officer |
|
Karen S. Lynch
Independent Director |
|
Lisa P. Britt
Chief Human Resources Officer & Senior VP |
|
Marc N. Casper
Chairman, President & Chief Executive Officer |
|
Michel Lagarde
Chief Operating Officer & Executive Vice President |
|
Mike Shafer
Senior VP & President-Pharma Services Group |
|
Nelson J. Chai
Independent Director |
|
R. Alexandra Keith
Independent Director |
|
Rafael Tejada
Vice President-Investor Relations |
|
Ronald Storch
Chief Business Officer & Senior Vice President |
|
Ruby R. Chandy
Independent Director |
|
Ryan Snyder
Chief Information Officer & Senior Vice President |
|
Scott M. Sperling
Lead Independent Director |
|
Sebastian Pacios
Senior Vice President-Clinical Research |
|
Stephen Williamson
Chief Financial Officer & Senior Vice President |
|
Tom B. Shropshire
Senior Vice President & General Counsel |
|
Tyler E. Jacks
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.